Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence.

Surgery - 1 Dec 2012

Prescott Jason D, Sadow Peter M, Hodin Richard A, Le Long Phi, Gaz Randall D, Randolph Gregory W, Stephen Antonia E, Parangi Sareh, Daniels Gilbert H, Lubitz Carrie C

Abstract excerpt

BACKGROUND: Papillary thyroid cancer (PTC) recurrence risk is difficult to predict. No current risk classification system incorporates BRAF mutational status. Here, we assess the incremental value of BRAF mutational status in predicting PTC recurrence relative to existing recurrence risk algorith...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Papillary
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphatic Metastasis

Share to Neoplasm Recurrence, Local

Share to Proto-Oncogene Proteins B-raf

Share to Risk Assessment

Share to Thyroid Neoplasms

Share to Thyroidectomy

Source

Open in PubMed Open full text

Identifiers

PMID: 23158172
DOI: 10.1016/j.surg.2012.08.039
PMCID: PMC3502879

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23158172-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence.PMID 23158172Read ↗

BRAFV600E Mutation is Associated with an Increased Risk of Papillary Thyroid Cancer Recurrence.Semantic proximity Read ↗

Association Between <i>BRAF</i> V600E Mutation and Recurrence of Papillary Thyroid CancerSemantic proximity Read ↗

Analysis of prognostic factors and establishment of a recurrence risk prediction model for papillary thyroid carcinoma based on BRAF stratification.Semantic proximity Read ↗

BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.Semantic proximity Read ↗

Tumor mutation burden-assisted risk stratification for papillary thyroid cancer.Semantic proximity Read ↗

Response to therapy of papillary thyroid cancer of known BRAF status.Semantic proximity Read ↗

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.Semantic proximity Read ↗

BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.Semantic proximity Read ↗

Recurrence of Papillary Thyroid Cancer: A Systematic Appraisal of Risk FactorsSemantic proximity Read ↗

BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer.Semantic proximity Read ↗

The <i>BRAF</i> mutation is useful for prediction of clinical recurrence in low‐risk patients with conventional papillary thyroid carcinomaSemantic proximity Read ↗

BRAF(V600E) Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.